Don't Judge a Stock by Its High or Low Share Price
Three ongoing trends contribute to the existence of a $1,000+ share price club among the S&P 500 companies.
Charles Rotblut
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Three ongoing trends contribute to the existence of a $1,000+ share price club among the S&P 500 companies.
Charles Rotblut
A few stocks grading highly on the criteria used in each of our eight model stock portfolios present a diversified sample.
Charles Rotblut
Charles Schwab offers funds that could make suitable options for AAII’s Asset Allocation Models.
Cynthia McLaughlin
Cynthia McLaughlin
Jack Gilleland
| Share Statistics | LLY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,231,686.1 | $421.0 | 100% |
|
| Shares Out (Mil) | 893.4 | 46.5 | 93% |
|
| Institutional Ownership | 99.8% | 82.0% | 94% |
|
| Float (Mil) | 888.4 | 48.3 | 90% |
|
| Beta | 0.39 | 0.68 | 21% |
|
| Avg Daily Volume (000s) | 3,056 | 348 | 86% |
|
| Price Change (52-week) |
35.3% | 52.0% | 79% |
|
| Growth | LLY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 21.6% | 6.6% | 83% |
|
| Net Income (5yr) | 27.2% | (1.6%) | 82% |
|
| EPS (5yr) | 27.6% | 15.1% | 79 |
|
| Dividends (5yr) | 15.2% | 0.0% | 99% |
|
| Cash Flow (5yr) | 25.2% | (15.1%) | 83% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 17 | 26 | 28 | |
| Current EPS | $11.251 | $35.473 | $50.797 | |
| Month Ago EPS | $10.095 | $34.896 | $47.210 | |
| # Rev Up | 1 | 4 | 0 | |
| # Rev Down | 1 | 4 | 1 | |
| Three Months Ago EPS | $9.976 | $36.725 | $47.330 | |
| Year/Year Chg | 55.8% | 54.6% | 152.9% | |
| Financials | LLY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $86,462 | $289 | 98% |
|
| Net Income (TTM) (Mil) | $27,580 | ($11) | 100% |
|
| EPS (TTM) | $30.863 | ($0.600) | 99% |
|
| Operating Cash Flow (TTM) (Mil) | $30,645 | ($7) | 99% |
|
| Net Cash Flow (TTM) (Mil) | ($4,907) | $1 | 0% |
|
| Long-Term Debt (Q1) (Mil) | $46,986 | $4 | 98% |
|
| Enterprise Value (Q1) (Mil) | $1,329,657 | $331 | 100% |
|
| Valuation | LLY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 30.60 | 2.27 | 98% |
|
| P/E | 44.9 | 24.1 | 85% |
|
| Dividend Yield | 0.5% | 0.0% | 62% |
|
| PEG (5yr hist) | 1.6 | 1.2 | 64% |
|
| Ratios | LLY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 83.6% | 69.4% | 91% |
|
| Net Margin | 31.9% | 3.9% | 90% |
|
| ROA | 21.0% | (23.8%) | 96% |
|
| ROE | 86.1% | (24.7%) | 96% |
|
| Liabilities to Assets | 72.8% | 32.0% | 69% |
|
| F-Score | 8 | 3 | 93% |
|
Eli Lilly and Company did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors